Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
Presentation Selected for Best of EASL Summary Slides
Altimmune to Host a
Details for the oral presentation are as follows:
|Title:||Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibro-inflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial (Presentation ID OS-063)|
Best of EASL Summary Slide Deck
Dr. Harrison’s presentation was selected for the Best of EASL Summary Slides, a compendium highlighting the most noteworthy contributions to the 2023 EASL program. A copy of the presentation will be accessible on the Events section of the Altimmune website.
Altimmune will host a reception in
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Investor & Media Contacts:
Chief Financial Officer
Source: Altimmune, Inc